Enter at least 3 characters
HOME > Press
 
Chiesi Global Rare Diseases Releases Report on the Burden of Care for Rare Diseases and Its Economic Impact on European Citizens
New research from Chiesi analyses the economic burden for 23 rare diseases across five therapeutic areas in three EU Member States and will be launched during a panel at the World Orphan Drug...
1/11
PRESS RELEASE
Chiesi Global Rare Diseases Releases Report on the Burden of Care for Rare Diseases and Its Economic Impact on European Citizens
Climate Change Threatens Respiratory Patients' Quality of Life Stretching Beyond Physical Health to Overall Well-Being, New Report Warns
Chiesi Group mid-year financial results demonstrate strong growth for 2023
Chiesi reçoit l’autorisation de mise sur le marché pour la pegunigalsidase alfa dans le traitement de la maladie de Fabry de la part des autorités européennes et américaines
A l’occasion du sommet Choose France 2023, Chiesi annonce une nouvelle vague d’investissements sur son site industriel de la Chaussée-Saint-Victor, à hauteur de 60 millions d’euros pour la période 2023-2026
Démocratiser la mesure du souffle : un enjeu majeur de santé publique
Chiesi fait l’acquisition de Amryt Pharmaceuticals
Le groupe Chiesi poursuit sa croissance en 2022
CHIESI ET AFFIBODY S’ASSOCIENT POUR DÉVELOPPER DE NOUVEAUX TRAITEMENTS INNOVANTS DANS LES MALADIES RESPIRATOIRES
Chiesi appoints Giuseppe Accogli as new Group CEO
Chiesi renforce son engagement dans la lutte contre les maladies rares
Chiesi Group continues to grow
Chiesi Group calls for #ActionOverWords in the fight against climate change
Chiesi organizes the 1st roundtable dedicated to the mission-oriented companies in the field of health & well-being
Chiesi continues cultural transformation with new visual identity that mirrors patients’ language and experiences
Chiesi Farmaceutici President appointed Knight of the Légion d’Honneur
Moderna and Chiesi Group Establish Collaboration to Discover and Develop mRNA Therapeutics for Pulmonary Arterial Hypertension (PAH).
Chiesi publishes its annual report: Group generates almost €2 billion and obtains B Corp certification in 2019
Chiesi Group increases support measures and announces new funds for employees, patients and healthcare providers in response to COVID-19 pandemic
Chiesi France, fait évoluer son Comité de Direction avec 3 nouvelles nominations
Chiesi, accompagné par IBM, lance WeStart, son premier programme d’innovation ouverte fondé sur le partage et la collaboration.
Chiesi outlines €350 million investment and announces the development of the first carbon minimal pressurised Metered Dose Inhaler (pMDI) for Asthma and COPD
Le groupe Chiesi reçoit le prix Diversity Leaders Award 2020
Chiesi Group is the largest pharmaceutical group in the world to be awarded B Corp certification
COPD, a disease still underestimated by Europeans
The Chiesi Group is one of the 8 Italian companies invited by Macron to the French International Summit in Versailles
CHIESI FRANCE INAUGURATES HIS NEW OFFICES AT BOIS-COLOMBES
Chiesi France executive committee evolution
Chiesi France moving Forward
Appointment of Patrice Carayon